Tag: non-small-cell lung cancer
Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in...
Phase 2 LUMINOSITY Study Shows Positive Results for Telisotuzumab Vedotin in for Patients with Previously Treated Non-Small Cell Lung Cancer
What to Expect at ASCO ’23: Mythic Therapeutics’ MYTX-011 Trial In...
During the annual meeting of the American Society of Clinical Oncology (ASCO) held June 2-6, 2023 in Chicago, Illinois, and online, cancer researchers and...
Daiichi Sankyo and AstraZeneca Sign Collaboration with Lung Cancer Research Foundation;...
The Lung Cancer Research Foundation (LCRF), a leading nonprofit organization focused on funding innovative, high-reward research with the potential to extend survival and improve...
Eisai and Bristol Myers Squibb Sign Global Strategic Collaboration to Jointly...
In a statement released earlier today, Eisai and Bristol-Myers Squibb confirm that the two companies have entered into an exclusive global strategic collaboration agreement...
ESMO 2020: Updated Interim Data of XMT-1536 Supports Continued Development in...
Updated interim phase I date for the safety, tolerability, and efficacy porting for the ovarian cancer cohort of an ongoing expansion study evaluating XMT-1536...
Daiichi Sankyo and AstraZeneca to Jointly Evaluate Patritumab Deruxtecan + Osimertinib...
Earlier this week Daiichi Sankyo and AstraZeneca confirmed that the companies had entered into a clinical trial collaboration with to evaluate the combination of...
Mersana Reports Updated Data from the XMT-1536 Phase I Dose Escalation...
Mersana Therapeutics, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet...
Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate
A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...
AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...
A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...
Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...
Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...
